CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 103 enrolled
Drug / intervention
Ruxolitinib Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05456529
NCT05456529Phase 3Completed
CompareCT.gov

A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis

Incyte Corporation·interventional·Posted Jul 13, 2022·Updated Jun 25, 2025

In Brief

A Phase 3 clinical trial evaluating Ruxolitinib Cream for Atopic Dermatitis (AD). Completed, enrolled 103 participants across 38 sites in 3 countries.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis (AD)
CountriesCanada, Poland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedJul 13, 2022
Enrollment StartSep 1, 2022
Primary CompletionMay 17, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.0 years ago

Interventions

Ruxolitinib Creamdrug

Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.